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PODIUM SESSION III:  
MEDICARE STUDIES  
 
MD1  
IMPACT OF MEDICARE PART D COVERAGE ON HEALTH OUTCOMES IN END-
STAGE RENAL DISEASE  
Park H1, Rascati KL1, Lawson KA1, Barner J1, Richards K1, Malone DC2 
1The University of Texas at Austin, Austin, TX, USA, 2University of Arizona, Tucson, AZ, USA  
OBJECTIVES: To evaluate the impact of Medicare Part D coverage on health 
outcomes in dialysis patients. METHODS: A retrospective analysis (2006-2009) of 
the United States Renal Data System was conducted for Medicare-eligible 
dialysis patients. Cardiovascular disease morbidity, health care utilization and 
expenditures, medication adherence, and mortality rates were compared, 
categorized based on patients’ Part D coverage in 2007 for those who: 1) did not 
reach the coverage gap (cohort 1); 2) reached the coverage gap but not 
catastrophic coverage (cohort 2); 3) reached catastrophic coverage (cohort 3); and 
4) did not reach the coverage gap but received a low-income subsidy (cohort 4). 
Cox proportional hazard models, Kaplan-Meier methods, logistic regressions, 
generalized linear models, and generalized estimating equations were used. 
RESULTS: A total of 11,732 patients were identified. After adjusting for 
demographic and clinical factors, patients in cohort 2 and cohort 3 had 40% and 
36% increased risk of cardiovascular disease (odds ratio (OR)=1.40, 95% 
confidence interval (CI):1.19-1.65; OR=1.36, 95% CI:1.09-1.71); and had 33% and 
32% higher death rates compared to those in cohort 4, respectively (hazard ratio 
(HR)=1.33, 95% CI:1.25-1.42; HR=1.32, 95% CI:1.22-1.43). Patients in cohort 2 were 
more likely to be nonadherent to medications for diabetes (relative risk (RR)=6.91, 
95% CI:5.46-8.73), hypertension (RR=3.59, 95% CI:3.12-4.14), hyperlipidemia 
(RR=4.57, 95% CI:3.74-5.57), hyperphosphatemia (RR=3.52, 95% CI:2.96-4.18), and 
hyperparathyroidism (RR=2.55, 95% CI:1.82-3.56) after reaching the coverage gap. 
These patients had total medical costs that were 5% higher (OR=1.05, 95% CI: 
1.03-1.08) due to increased rates of hospitalization (OR=1.26, 95% CI:1.12-1.41) 
and outpatient visits (OR=1.25, 95% CI:1.02-1.52), despite 14% lower pharmacy 
costs (OR=0.86, 95% CI:0.83-0.89) compared to patients in cohort 4. 
CONCLUSIONS: Reaching the Part D coverage gap was associated with decreased 
medication adherence and unfavorable clinical and economic outcomes in 
dialysis patients.  
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SKELETAL-RELATED EVENTS AND MORTALITY AMONG SEER-MEDICARE 
PATIENTS WITH METASTATIC PROSTATE CANCER: THE IMPLICATIONS OF 
MEASUREMENT APPROACH  
Onukwugha E1, Yong C1, Mullins CD1, Seal B2, Hussain A3 
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Bayer HealthCare 
Pharmaceuticals, Inc., Pine Brook, NJ, USA, 3University of Maryland School of Medicine, 
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OBJECTIVES: To investigate the survival impact of skeletal-related events (SRE) 
as a cluster of events and by type of SRE, including pathological fracture (PF), 
spinal cord compression (SCC), and bone surgery (BS), using three claims-based 
approaches. METHODS: We analyzed prostate cancer (PCa)-specific and all-cause 
mortality among elderly SEER-Medicare men diagnosed with metastatic PCa 
between 2000 and 2007. PF, SCC, and BS were identified from Medicare claims 
and used to define SRE using a base case and alternative approaches (AltA). The 
approaches included a base case: SRE follows claims with a bone metastasis (BM) 
ICD-9 diagnosis code; AltA-1: SRE includes BM diagnosis code on the SRE claim; 
AltA-2: SRE is not anchored to BM. A Cox model provided covariate-adjusted 
hazard ratios (HR) in the full sample (FS) and in a propensity-score matched 
sample (PSMS). RESULTS: Application of inclusion/exclusion criteria resulted in 
7,062 patients in FS (1,776 in PSMS). PCa-specific mortality was 54% during 
median (mean) follow-up of 609 (837) days. Using the base case approach, the 
prevalence of any SRE, SCC, PF, and BS were: 12.6%, 7.4%, 4.3% and 1.9%. SRE 
prevalence was 9.7% for AltA-1 and 17.1% for AltA-2. The HR (95% CI) associated 
with any SRE was 1.27 (1.16–1.39) for the base case approach, 1.31 (1.18–1.45) for 
AltA-1, and 1.07 (0.98–1.16) for AltA-2. Results were qualitatively similar for all-
cause mortality. The HRs for SCC and PF were statistically significantly 
associated with PCa-specific mortality across approaches. The results for BS 
were sensitive to the SRE definition. Results for SCC and BS were unchanged 
from the base case approach when using the PSMS. CONCLUSIONS: The 
prevalence of SREs and their association with survival in the elderly depends on 
the definition of SREs. A validated claims-based measure of SRE is warranted to 
better understand the burden of SRE among PCa patients.  
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ASSOCIATION BETWEEN INHALED ANTICHOLINERGICS USE AND ALL-CAUSE 
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OBJECTIVES: To examine the association between inhaled anticholinergics (IAC) 
use and all-cause mortality among elderly individuals with respiratory 
conditions after controlling for co-occurring chronic physical and mental health 
conditions and self reported perceived health status. METHODS: Retrospective 
cross-sectional analyses of survey data from multiple years (2000-2005) of 
Medicare Current Beneficiary Survey (MCBS). Generic and brand names of IACs 
were used to identify IAC utilization from the self-reported prescription 
medication files. All-cause mortality was assessed using the vital status recorded 
in the enrollment file. Unadjusted group differences in mortality and IAC 
utilization rates were tested using chi-square statistic. Logistic regressions 
independent variables entered in separate blocks were used to analyze the 
association between IAC use and all-cause mortality after controlling for co-
occurring conditions, demographic, socio-economic, health, functional status, 
smoking and obesity. Self-reported health status was used as a stratifying 
variable to control for selection bias associated with IAC use. All analyses 
accounted for the complex design of the MCBS. RESULTS: Overall, 21% of the 
elderly Medicare beneficiaries used IAC. IAC use was significantly higher among 
those who reported fair to poor health compared to those with excellent to good 
health (28.5% vs. 18.0%). IAC use was not associated with all-cause mortality in 
the overall model. However, findings from the stratified regression indicated that 
IAC use was beneficial for those with fair to poor health [AOR: 0.62, 95% CI: 0.45, 
0.85]. CONCLUSIONS: Among elderly individuals with respiratory conditions who 
reported poor perceived health status, IAC use may be beneficial in reducing the 
risk of all-cause mortality.  
 
MD4  
GEOGRAPHIC VARIATION IN LOCAL MEDICARE COVERAGE FOR PART B 
BIOLOGICS  
Saret CJ, Cangelosi MJ, Chambers JD, Cohen JT, Neumann PJ 
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OBJECTIVES: In the absence of a national Medicare policy for a new technology 
in the United States, each of 13 regional Medicare Administrative Contractors 
(MACs) makes independent coverage policies for the program. Our objective was 
to evaluate geographic variation in regional coverage policies for selected 
Medicare Part B (non-self-administered) biologics. METHODS: We considered 
four biologics indicated for rheumatoid arthritis, psoriatic arthritis, psoriasis, 
Crohn’s disease, and/or ankylosing spondylitis (n=4 biologics across the 13 
regional MACs covering 52 possible policies). To identify MAC coverage policies, 
we used the Centers for Medicare and Medicaid Services’ (CMS’s) Medicare 
Coverage Database (www.cms.gov/medicare-coverage-database), which details 
the program’s coverage policies. For each of the biologics, we determined 
whether there was a national coverage decision. If not, we established whether 
each MAC had a formal coverage policy or whether it adjudicated claims for the 
biologic on a “case-by-case” basis. We further classified MAC coverage policies by 
whether they contained any coverage restrictions, e.g., limited to “moderately to 
severely active rheumatoid arthritis” or “inadequate response to one or more 
TNF antagonist therapies.” RESULTS: As of January 2013, none of the biologics 
had a national coverage decision. Six of the 13 MACs had issued a total of 16 
coverage policies associated with these biologics. The other seven MACs had no 
formal coverage policies for any of the biologics. Thus, MACs had issued formal 
coverage policies in 16 of the possible 52 cases; the other 36 scenarios were 
adjudicated on a case-by-case basis. Nine of the 16 formal coverage policies 
contained coverage restrictions; the remaining seven did not. CONCLUSIONS: 
There exists a great deal of variation in local Medicare coverage for Part B 
biologics. Most decisions by MACs for the biologics considered have been made 
on a case-by-case basis, which may lead to administrative burden and 
inconsistent access.  
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PAYER PERSPECTIVES ON DRUG PRICING, COVERAGE, AND REIMBURSEMENT IN 
OPHTHALMOLOGIC ORPHAN CONDITION IN THE UNITED STATES  
Gavaghan M1, Abraham J1, Pauer L2 
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OBJECTIVES: Traditionally, treatments for orphan conditions have faced fewer 
pricing and reimbursement hurdles by managed care organizations in the United 
States. Given the downward pressure on health care spending and anticipated 
full implementation of the Affordable Care Act, we sought to better understand 
whether payer perspectives were evolving to more restrictive coverage and 
downward pricing pressure for treatments of orphan conditions like posterior 
non-infectious uveitis. METHODS: We conducted 20 in-depth, qualitative, 60-
minute interviews with key decision-makers (medical and pharmacy directors) 
at managed care organizations in the United States. Interviews included 
questions related to current orphan drug policy, awareness of posterior non-
infectious uveitis (orphan condition), opinions on a treatment for posterior non-
infectious uveitis currently under development, and potential pricing and 
reimbursement based on anticipated clinical trial endpoints. RESULTS: Of the 20 
medical and pharmacy directors interviewed as part of this research, 10 (50%) 
felt that orphan treatment coverage policies will evolve independent of future 
health care changes due to the full implementation of the Affordable Care Act. 
When asked to consider factors that impact coverage policies for a novel orphan 
treatment for posterior non-infectious uveitis, 14 (70%) felt that the clinical 
effectiveness and clinical utility of the product is the most important factor for 
coverage, though budget impact may increase coverage specifications. 
CONCLUSIONS: The evolving payer landscape due to the implementation of ACA 
indicated increasing levels of scrutiny about coverage of orphan drugs, but 
payers interviewed for this research felt that treatments of posterior non-
infectious uveitis will be covered, though the budget impact of treatment may 
increase utilization management at the pharmacy level.  
 
PR2  
SHORTCOMINGS OF EQ-5D IN A VALUE-BASED PRICING FRAMEWORK  
Tordrup D1, Mossman J2, Kanavos P3 
1London School of Economics, London, UK, 2European Federation of Neurological Associations, 
Dublin, Ireland, 3London School of Economics and Political Science, London, UK  
